SUPPLEMENTARY MATERIAL

Enthesitis and Dactylitis Resolution With Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials

Shawn G. Kwatra, Saakshi Khattri, Ahmad Z. Amin, Roberto Ranza, Blair Kaplan, Linyu Shi, Byron Padilla, Ahmed M. Soliman, Dennis McGonagle

S. G. Kwatra
Department of Dermatology, John Hopkins University School of Medicine, Baltimore, MD, USA
S. Khattri
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
A. Z. Amin
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
R. Ranza
Rheumatology Unit, Hospital das Clínicas, Federal University of Uberlândia, Uberlândia, Brazil
B. Kaplan ● L. Shi ● B. Padilla ● A. M. Soliman
AbbVie Inc., North Chicago, IL, USA
D. McGonagle
Division of Rheumatology, University of Washington, Seattle, WA, USA
D. McGonagle
Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, UK

Correspondence:
Shawn G. Kwatra
Department of Dermatology
John Hopkins University School of Medicine
601 N Caroline St, 8th Floor
Baltimore, MD 21287, USA
e-mail: kwatra.shawn@gmail.com. Phone: (919) 740-0277

Supplementary Fig. 1 Proportion of patients achieving resolution of enthesitis, dactylitis, or both by biologic therapy experience. Resolution of enthesitis in biologic-naïve patients (RZB, *n* = 368; PBO, *n* = 376) (a) and biologic-experienced patients (RZB, *n* = 76; PBO, *n* = 72) (b), resolution of dactylitis in biologic-naïve patients (RZB, *n* = 165; PBO, *n* = 175) (c) and biologic-experienced patients (RZB, *n* = 23; PBO, *n* = 29) (d), and resolution of both enthesitis/dactylitis in biologic-naïve patients (RZB, *n* = 107; PBO, *n* = 122) (e) and biologic-experienced patients (RZB, *n* = 21; PBO, *n* = 25) (f).



Missing data were imputed using nonresponder imputation incorporating multiple imputation to handle missing data resulting from COVID-19 in the double-blind period and nonresponder imputation (as observed) in the open-label extension period.
*$p < 0.05$; **$p < 0.01$; ***$p < 0.001$ vs PBO.
CI confidence interval, *PBO* placebo, *RZB* risankizumab.

Supplementary Fig. 2 Mean change in LEI among patients with baseline enthesitis among biologic-naïve patients (a) and biologic-experienced patients (b) and mean change in LDI among patients with baseline dactylitis among biologic-naïve patients (c) and biologic-experienced patients (d).



Mixed-effect model repeated measurement analysis was used for the double-blind period; as-observed data were used for the open-label extension period.

*$p < 0.05$; **$p < 0.01$ vs PBO.

CI confidence interval, *LDI* Leeds Dactylitis Index, *LEI* Leeds Enthesitis Index, *LS* least squares, *PBO* placebo, *RZB* risankizumab.